AstraZeneca, maker of the Covishield vaccine, has admitted in a UK court that its inoculation can rarely cause Thrombosis with Thrombocytopenia Syndrome (TTS). TTS involves blood clotting alongside low platelet counts, with symptoms like severe headaches and abdominal discomfort. The admission came amidst a lawsuit over alleged vaccine-related injuries, with 51 cases filed seeking compensation. While AstraZeneca disputes some claims, it has conceded the vaccine’s potential for TTS, though the exact causal mechanism remains unknown. The acknowledgment follows legal pressure, highlighting the need for transparency and accountability in vaccine safety.